Back
44
Day Range
$29.22
$30.69
52-Week Range
$8.64
$38.00
Volume
4,058,471
50D / 200D Avg
$33.28
/
$26.76
Prev Close
$29.30
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 17.5 | 0.4 |
| P/B | — | 2.9 |
| ROE % | — | 3.7 |
| Net Margin % | 17.0 | 3.9 |
| Rev Growth 5Y % | 11.9 | 10.0 |
| D/E | — | 0.2 |
Analyst Price Target
Hold
$43.75
+48.9%
Low: $36.00
High: $50.00
Forward P/E
9.4
Forward EPS
$3.12
EPS Growth (est.)
+0.0%
Est. Revenue
1.2 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$4.15
$4.01 – $4.32
|
1.4 B | 1 |
| FY2029 |
$3.84
$3.71 – $4.00
|
1.4 B | 1 |
| FY2028 |
$3.81
$3.68 – $3.97
|
1.3 B | 1 |
Key Takeaways
Revenue grew 11.87% annually over 5 years — strong growth
Earnings grew 10400.00% over the past year
Net margin of 16.95% shows strong profitability
Negative free cash flow of -93.00M
PEG of 0.00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.58%
Growth
Revenue Growth (5Y)
11.87%
Revenue (1Y)4.29%
Earnings (1Y)10400.00%
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROIC77.67%
Net Margin16.95%
Op. Margin21.15%
Safety
Debt / Equity
N/A
Current Ratio0.71
Interest Coverage5.82
Valuation
P/E Ratio
17.46
P/B RatioN/A
EV/EBITDA14.59
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4.29% | Revenue Growth (3Y) | 6.47% |
| Earnings Growth (1Y) | 10400.00% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 11.87% | Earnings Growth (5Y) | 0.60% |
| Profitability | |||
| Revenue (TTM) | 1.24B | Net Income (TTM) | 210.00M |
| ROE | N/A | ROA | 17.44% |
| Gross Margin | 80.23% | Operating Margin | 21.15% |
| Net Margin | 16.95% | Free Cash Flow (TTM) | -93.00M |
| ROIC | 77.67% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.71 |
| Interest Coverage | 5.82 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 17.46 | P/B Ratio | N/A |
| P/S Ratio | 2.96 | PEG Ratio | 0.00 |
| EV/EBITDA | 14.59 | Dividend Yield | 0.00% |
| Market Cap | 3.67B | Enterprise Value | 3.82B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.24B | 1.19B | 1.09B | 901.00M | 791.00M |
| Net Income | 210.00M | 2.00M | -129.00M | -44.00M | 205.00M |
| EPS (Diluted) | 1.64 | 0.02 | 0.01 | -0.37 | 1.31 |
| Gross Profit | 994.00M | 957.00M | 919.00M | 750.00M | 664.00M |
| Operating Income | 262.00M | 32.00M | -156.00M | -81.00M | 213.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.20B | 1.32B | 1.77B | 1.78B | 1.83B |
| Total Liabilities | 1.30B | 1.67B | 1.96B | 1.73B | 1.63B |
| Shareholders' Equity | -98.00M | -348.00M | -191.00M | 51.28M | 203.00M |
| Total Debt | 351.00M | 375.00M | 283.00M | 277.00M | 286.00M |
| Cash & Equivalents | 195.00M | 319.00M | 316.00M | 778.18M | 1.10B |
| Current Assets | 652.00M | 839.00M | 1.27B | 1.27B | 1.44B |
| Current Liabilities | 914.00M | 939.00M | 1.29B | 1.02B | 804.00M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#209 of 326
Recent Activity
Entered
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026